Searched for
ASSERTIO HOLDINGS
Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 millionZydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...
Stocks in news: Prime Focus, Groww, GIC RE, Wipro, NykaaIndian benchmark indices traded with a positive bias, with the Nifty consolidating near the 24,000 mark and closing near its day's high. Se...
Zydus Lifesciences completes acquisition of AssertioThe company has successfully completed the cash tender offer, through wholly-owned subsidiary, Zara Merger Sub Inc, for all the outstanding...
Stock Radar: Zydus Lifesciences stock breaks out from inverse head & shoulder pattern to hit fresh 52-week high; time to buy?Zydus Lifesciences Ltd. broke out from an inverse head & shoulder pattern, hitting fresh 52-week highs and suggesting continued momentum. E...
Stocks in news: Lenskart, Apollo Hospitals, ZEE, BPCL, HindalcoIndian markets navigated a sideways trend, with analysts urging caution until the 24,000 mark is reclaimed. Key stocks like Lenskart, Apoll...
Zydus Lifesciences to pursue acquisitions in specialty, rare diseasesZydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology bus...
Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisitionZydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. T...
Zydus to buy Assertio for $166.4 millionZydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structure...
Tata group’s Impetis out-licenses arthritis and autoimmune drugs to VyomeIn a significant move for medical innovation, Impetis Biosciences, a subsidiary of Tata group, has teamed up with Vyome Holdings from the U...
Zydus Lifesciences acquires US pharma firm Assertio for $166 millionIn a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...